Key result
Moderate- to high-dose LLT is linked to ~15% lower dementia risk in high-risk ASCVD.
Why the study?
Atherosclerotic cardiovascular disease (ASCVD) and Alzheimer's disease (AD) dementia share common risk factors, yet the role of ASCVD prevention therapies such as lipid-lowering therapy and antiplatelets in preventing dementia and AD dementia across ASCVD risk profiles was not fully understood.
Does lipid-lowering therapy and aspirin use reduce dementia and Alzheimer's disease dementia diagnoses in primary prevention patients stratified by ASCVD risk?
Cohort (n=347,128)
Yes
Does lipid-lowering therapy and aspirin use reduce dementia and Alzheimer's disease dementia diagnoses in primary prevention patients stratified by ASCVD risk?
Answers are grounded in this paper and cite their sources.
In a large primary prevention cohort, higher baseline ASCVD risk is linked to increased dementia and AD risk, whereas aspirin and moderate- to high-dose lipid-lowering therapy are associated with reduced dementia risk among high-risk individuals.
Background Atherosclerotic cardiovascular disease (ASCVD) and Alzheimer's disease (AD) dementia share common risk factors. However, the role of ASCVD prevention therapies in AD dementia prevention is not fully understood. We examined the effect of LLT and antiplatelets with dementia and AD dementia diagnoses across ASCVD risk profiles. Methods We used data from primary prevention registry derived from a large healthcare network. Multivariable Cox proportional models were generated to study dementia and AD dementia diagnoses, stratified by ASCVD risk profiles. Impact of aspirin and LLT use on dementia and AD dementia diagnoses was assessed in adjusted models. Results Among n= 347,128, 2.4% developed dementia and 2.0% developed AD dementia over a median follow‐up of 7.94 years. In adjusted models, dementia (HR, 2.59; 95% CI [2.29–2.92]) and AD dementia (HR, 2.85; 95% CI [2.49–3.25]) was higher in high risk patients. Low and high‐dose aspirin among high ASCVD risk had lower dementia (HR, 0.88; 95% CI, [0.77–1.00] and HR, 0.83; 95% [CI 0.77–0.90]) and AD dementia (HR, 0.83; 95% CI [0.77–0.91] and HR, 0.85; 95% CI [0.73–0.97]). Similarly, moderate‐ to high‐dose LLT use among high ASCVD risk groups was associated with lower dementia (HR, 0.85; 95% CI [0.79–0.93]) and AD dementia (HR, 0.85; 95% CI [0.78–0.93]). Conclusions Higher baseline ASCVD risk was associated with increased risk of dementia and AD dementia diagnoses. Aspirin and moderate‐ to high‐dose LLT use among patients with high ASCVD risk was associated with lower dementia and AD dementia risk.
No takes yet. Share an insight, caveat, or question.
Kainat et al. (2026) conducted a cohort in Primary prevention of atherosclerotic cardiovascular disease (ASCVD) (n=347,128). Lipid-lowering therapy (statin) and aspirin use vs. Non-use across ASCVD risk profiles was evaluated on Dementia and Alzheimer's disease (AD) dementia diagnoses (HR 0.85, 95% CI 0.79-0.93). Moderate- to high-dose LLT and aspirin use among high ASCVD risk patients were associated with lower dementia risk (LLT HR 0.85, 95% CI 0.79-0.93; high-dose aspirin HR 0.83, 95% CI 0.77-0.90).
Synapse has enriched 10 related papers. Consider them for comparative context: